anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Single topical application: 80 +/- 2 milligrams (mg) (2.0 +/- 0.05 mg/centimeter\^2) of ChapStick Lip Moisturizer (CLM) Original will be applied to the assigned test site using a fingercot. The test product will be evenly spread over the test site using light pressure.
Stable aqueous solutions are produced by a process in which dimethylaminophenyldimethylpyrazolone and phenyldimethylpyrazolone are dissolved in water to form an aqueous solution containing at least 5 gm. dimethylaminophenyldimethylpyrazolone per 100 cc., the solution is filled into ampoules, and the ampoules are heated.  The step of heating the solution in the ampoules stabilizes the solutions against crystallization.  Preferably 0.8 to 1.2 parts by weight of phenyldimethylpyrazolone are employed to 1 part by weight of dimethylaminophenyldimethylpyrazolone.  In examples of the process solutions are prepared (a) containing 15 parts by weight of each pyrazolone derivative made up to 100 parts by volume with water; (b) containing 20 parts of dimethylaminophenyldimethylpyrazolone, and 24 parts of phenyldimethylpyrazolone dissolved in 100 parts of water. Other medicaments, e.g codeine salts, calcium salts or p-aminobenzoyldiethylaminoethanol or its hydrochloride, can be added to the solutions.  Specification 9916/40 (as open to inspection under Sect. 91) is referred to.ALSO:Stable aqueous solutions are produced by a process in which dimethylaminophenyl-dimethylpyrazolone and phenyldimethylpyrazolone are dissolved in water to form aqueous solutions containing at least 5 gm dimethylaminophenyldimethylpyrazolone per 100 ccs., the solution is filled into ampules, and the ampules are heated.  The step of heating the solution in the ampules stabilises the solutions against crystallisation.  Preferably 0.8 to 1.2 parts by weight of phenyldimethylpyrazolone are employed to 1 part by weight of dimethylaminophenyldimethylpyrazolone.  In examples of the process solutions are prepared (a) containing 15 parts by weight of each pyrazolone derivative made up to 100 parts by volume with water; (b) containing 20 parts of dimethylaminophenyldimethylpyrazolone and 24 parts of phenyldimethylpyrazolone dissolved in 100 parts of water. Other medicaments, e.g. codeine salts, calcium salts or p-aminobenzoyldiethylaminoethanol or its hydrochloride, can be added to the solutions.  Specification 9916/40 (as open to inspection under Sect. 91) is referred to.
Risk Summary

There is no information regarding the presence of topically administered calcipotriene and betamethasone dipropionate in human milk, the effects on the breastfed infant, or the effects on milk production. Concentrations of calcipotriene in plasma are low after topical administration, and therefore, concentrations in human milk are likely to be low [see Clinical Pharmacology (12.3)]. It is not known whether topical administration of large amounts of betamethasone dipropionate could result in sufficient systemic absorption to produce detectable quantities in human milk (see Clinical Considerations). The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Calcipotriene and Betamethasone Dipropionate Topical Suspension and any potential adverse effects on the breastfed child from Calcipotriene and Betamethasone Dipropionate Topical Suspension or from the underlying maternal condition.

Clinical Considerations

To minimize potential exposure to the breastfed infant via breast milk, use Calcipotriene and Betamethasone Dipropionate Topical Suspension on the smallest area of skin and for the shortest duration possible while breastfeeding. Advise breastfeeding women not to apply Calcipotriene and Betamethasone Dipropionate Topical Suspension directly to the nipple and areola to avoid direct infant exposure [see Use in Specific Populations (8.4)].
PURPOSE: To obtain a composition comprising a conjugate made up of an antibody reactive to tumor-related antigen and a bioresponse regulatory substance segment, and capable of selectively localizing the regulatory substance inside a target cell. CONSTITUTION: This composition comprises a conjugate made up of an antibody reactive to tumor-related antigen (e.g. 15A8 antibody to breast cancer antigen, ZME-018 antibody to melanoma antigen) and a bioresponse regulatory substance segment (e.g. tumor necrosis factor, interleukin, interferon). The conjugate can be prepared as a gene fusion product which is afforded by fusion between a gene coding the antigen recognition site of an antibody and a gene coding bioresponse regulatory segment or cytoactive segment therefrom. Use of this composition as the conjugate enables the bioresponse regulatory substance to be localized inside a target cell and affords sufficient effect even at low levels of its administration owing to its persistence for a long time as a result of its reduced rate of metabolism or dissipation.
BACKGROUND: The incidence and prognostic predictors of heart failure (HF) without left ventricular systolic dysfunction (LVSD) in hypertrophic cardiomyopathy (HCM), particularly their differences in terms of developing LVSD (progression to end-stage) or sudden cardiac death (SCD), are not fully elucidated.
METHODS AND RESULTS: This study included 330 consecutive HCM patients with left ventricular ejection fraction (LVEF) ≥50%. HF hospitalization without LVSD and development of LVSD were evaluated as main outcomes. During a median follow-up of 7.3 years, the incidence of HF hospitalization without LVSD was 18.8%, which was higher than the incidence of developing LVSD (10.9%) or SCD (8.8%). Among patients who developed LVSD, only 19.4% experienced HF hospitalization without LVSD before developing LVSD. Multivariable analysis showed that predictors for HF hospitalization without LVSD (higher age, atrial fibrillation, history of HF hospitalization, and higher B-type natriuretic peptide concentrations) were different from those of developing LVSD (male sex, lower LVEF, lower left ventricular outflow tract gradient, and higher tricuspid regurgitation pressure gradient). Known risk factors for SCD did not predict either HF without LVSD or developing LVSD.
CONCLUSIONS: In HCM with LVEF ≥50%, HF hospitalization without LVSD was more frequently observed than development of LVSD or SCD during mid-term follow-up. The overlap between HF without LVSD and developing LVSD was small (19.4%), and these 2 HF events had different predictors.
PURPOSE:To prepare a solution of sodium hexametaphosphate in a short time, by adding a solution of sodium bicarbonate, potassium bicarbonate, potassium carbonate or sodium carbonate to powdery sodium hexametaphosphate. CONSTITUTION:The powdery sodium hexametaphosphate used as the raw material is prepared by weighing a definite amount of the powder having a purity of >= about 75%, and sterilizing with ultraviolet irradiation. The sodium bicarbonate, potassium bicarbonate, sodium carbonate or potassium carbonate has a purity of >= about 99%, and is used singly or in combination. The concentration of the solution is 1-20w/v%, and the solution is added to the powdery sodium hexametaphosphate. The dissolution completes within about 10-20min with slight agitation. A solution of sodium bicarbonate, etc. is added to the product to adjust the pH. The preparation process is carried out under an oseptic condition.
The placebo must be administered by intravenous route during 1 hour. It administered once during 1 day or once per day during 5 days.
This study will enroll 10 patients with diabetes who are admitted with a lower limb wound infection and 6 healthy volunteer control participants. The study will take place in an inpatient unit at Hartford Hospital for all patients and in the Clinical Research Center at Hartford Hospital for all healthy volunteers. All participants will receive 3 to 7 doses of tebipenem pivoxil hydrobromide (300 mg or 600 mg orally every 8 hours depending on renal function). A microdialysis probe (Mdialysis Inc., N. Chelmsford, MA) will be inserted into the subcutaneous soft tissue near the margin of the wound (patients) or in the thigh (healthy volunteers). The microdialysis probe is perfused with normal saline solution and samples are collected for the 8 hours following the final dose. A peripheral intravenous catheter will be inserted into an arm vein to collect blood samples simultaneously with microdialysis samples. Concentrations in tissue are compared with blood to determine percent penetration.
BACKGROUND: Atrial fibrillation (AF) is 1 of the most common types of arrhythmias. At present, the treatment for patients with AF mainly includes oral anticoagulants (OACs). Studies have shown that OACs are associated with cognitive decline in patients with atrial fibrillation; however, there is a lack of relevant evidence. This study used Bayesian network meta-analysis (NMA) to investigate the effects of different oral anticoagulants on cognitive decline in patients with AF.
METHODS: We systematically searched for clinical studies on oral anticoagulants in patients with AF in PubMed, Web of Science, Embase, and the Cochrane Library as of July 3, 2023. Cochrane's randomized controlled trial bias risk assessment tool and the Newcastle-Ottawa Scale were used to assess the bias risk of the included studies. The main outcome measure was decreased cognitive functioning.
RESULTS: Ten studies were included, including 2 RCTs and 7 RCSs, including 882,847 patients with AF. Five oral anticoagulants and 2 anticoagulants were included: VKAs (especially warfarin), Dabigatran, Edoxaban, Rivaroxaban, Apixaban, and Aspirin, Clopidogrel. The results of the mesh meta-analysis showed that VKAs were superior to warfarin in reducing the risk of cognitive decline in patients with AF (OR = -1.19, 95% CI (-2.35, -0.06), P < .05) (Table 5). The top 3 drugs in terms of the probability of reducing the incidence of cognitive impairment in patients with AF with different oral anticoagulants were VKAs (87%), rivaroxaban (62.2%), and dabigatran (60.8%).
CONCLUSION: Based on the results of this study, VKAs may be the best intervention measure for reducing the risk of cognitive decline in patients with AF. Owing to the limitations of this study, more high-quality randomized controlled trials with large sample sizes and multiple centers are required to provide more evidence.
Most adults with type 1 diabetes (T1DM) are either overweight or obese. As such, dietary management is recommended as an adjunct to insulin treatment to improve glycemic control and facilitate weight loss in these patients. Time-restricted eating (TRE) is a form of intermittent fasting that offers a simplified approach to treating obesity in T1DM. TRE typically involves restricting eating to 6 to 10 h per day, with water and medications allowed outside the eating window. This review examines the efficacy of TRE and other fasting protocols in improving weight and glycemic control in patients with obesity and T1DM. This review will also evaluate the safety of these regimens and provide advice to clinicians on implementing intermittent fasting in T1DM.
A pharmaceutical composition for treating or preventing depression disease comprising the extract of gardenia(Gardenia Jasminoides for. grandiflora) is provided to suppress activity of MAO(monoamine oxidase) without affecting internal organs influenced by sympathetic amine and serotonin. The pharmaceutical composition for treating or preventing depression disease comprises the extract of gardenia(Gardenia Jasminoides for. grandiflora) as an effective ingredient, wherein the gardenia(Gardenia Jasminoides for. grandiflora) extract is prepared by extracting gardenia(Gardenia Jasminoides for. grandiflora) with water of C1-C4 lower alcohol such as methanol, ethanol and butanol; the amount of gardenia(Gardenia Jasminoides for. grandiflora) extract is 0.1-50 wt.% based on the total weight of the composition; the composition is formulated as powder, granule, tablet, capsule, suspension, emulsion, syrup or aerosol; and the dosage of the gardenia(Gardenia Jasminoides for. grandiflora) extract is 0.0001-100 mg/kg per day.
ARRANON (nelarabine) is a prodrug of the cytotoxic deoxyguanosine analogue, 9-β-D-arabinofuranosylguanine (ara-G).

The chemical name for nelarabine is 2-amino-9-β-D-arabinofuranosyl-6-methoxy-9H-purine. It has the molecular formula C11H15N5O5 and a molecular weight of 297.27. Nelarabine has the following structural formula:

Nelarabine is slightly soluble to soluble in water and melts with decomposition between 209ºC and 217ºC.

ARRANON Injection is supplied as a clear, colorless, sterile solution in glass single-dose vials. Each vial contains 250 mg of nelarabine (5 mg nelarabine per mL) and the inactive ingredient sodium chloride (4.5 mg per mL) in Water for Injection, USP. ARRANON is intended for intravenous infusion.

Hydrochloric acid and sodium hydroxide may have been used to adjust the pH. The solution pH ranges from 5.0 to 7.0.
Nucleic acid compositions encoding Actiniidaen, e.g., Condylactin, chromoproteins and fluorescent mutants thereof, as well as the polypeptide compositions encoded by the same, are provided. The proteins of interest are proteins that are colored and/or fluorescent, where this feature arises from the interaction of two or more residues of the protein. Also of interest are proteins that are substantially similar to, or mutants of, the above specific proteins, including non-aggregating mutants and mutants with modulated oligomerization characteristics as compared to wild type. Also provided are fragments of the nucleic acids and the peptides encoded thereby, as well as antibodies to the subject proteins and transgenic cells and organisms. The subject protein and nucleic acid compositions find use in a variety of different applications. Finally, kits for use in such applications, e.g., that include the subject nucleic acid compositions, are provided.
The invention relates to coumarin lignan compounds extracted from Hibiscus hamabo Sieb.et Zucc. of Malvaceae Hibiscus, a preparation method thereof and application of the coumarin lignan compounds in anti-cancer, antioxidation and resistance to marine fouling. The coumarin lignan compounds are characterized in that the structural formula of compound A is represented as the chart on the right. The preparation method comprises utilizing alcohol with the concentration of 50-95% to carry out extraction, utilizing low-polarity solvent to perform extraction, utilizing macroporous resin to perform adsorption, and obtaining an active site where the coumarin lignan compounds are concentrated. The active ingredients obtained from the Hibiscus hamabo Sieb.et Zucc. by the extraction process and method are high in yield and purity, can inhibit activities of cancer cells such as HeLa, HepG2 and HL-60 and attaching activities of bugula neritina larvae and barnacle larvae and the like, have the effect of resisting marine fouling and can be used for preparing efficient marine antifoulants. Simultaneously, content of the active ingredients is determined, the content of the compound A is not lower than 3%, the effective dose is mastered easily, and the coumarin lignan compounds are safe and stable.
PURPOSE: Diagnosing cardiac amyloidosis (CA) is difficult due to nonspecific clinical symptoms and echocardiographic findings. Prior studies have suggested that apical sparing strain patterns may be diagnostically useful. With increasing strain usage, it remains unclear how specific this pattern is to diagnose CA. We analyzed strain patterns between CA and end-stage renal disease (ESRD) patient populations.
METHODS: Patients with ESRD proven negative for CA (n = 19) were compared to CA patients with CKD stage 3 or less (n = 25). The ESRD cohort was stratified based on time on dialysis. Echocardiographic longitudinal strain (LS) parameters were collected, including regional and global LS, echocardiographic, and demographic parameters. Relative apical LS was calculated using the following equation: average apical LS/(average mid LS + average basal LS).
RESULTS: No significant differences were found regarding regional strain or relative apical strain. Our study showed a sensitivity of 80% and specificity of 42% when using a relative apical strain ratio of >1. All groups demonstrated an apical sparing strain pattern visually on the bulls-eye plot.
CONCLUSION: ESRD demonstrates significant overlapping findings across various imaging modalities compared to CA. We demonstrated that relative apical sparing strain is nonspecific for CA among patients with ESRD. Our study calls into question the clinical value of relative apical-sparing stain patterns in identifying CA in an ESRD population and suggests that diagnostic evaluation should be driven by strong clinical suspicion and other imaging and demographic variables.
Etoposide is a second-line chemotherapy agent widely used for metastatic colorectal cancer. However, we discovered that etoposide treatment induced greater motility potential in four colorectal cancer cell lines. Therefore, we used microarrays to test the mRNA of these cancer cell lines to investigate the mechanisms of etoposide promoting colorectal cancer metastasis. Differentially expressed genes (DEGs) were identified by comparing the gene expression profiles in samples from etoposide-treated cells and untreated cells in all four colorectal cancer cell lines. Next, these genes went through the Gene Set Enrichment Analysis (GSEA), Gene Ontology (GO) and the Kyoto Encyclopedia of Genes and Genomes (KEGG) Pathway analysis. Among the top 10 genes including the upregulated and downregulated, eight genes had close interaction according to the STRING database: FAS, HMMR, JUN, LMNB1, MLL3, PLK2, STAG1 and TBL1X. After etoposide treatment, the cell cycle, metabolism-related and senescence signaling pathways in the colorectal cancer cell lines were significantly downregulated, whereas necroptosis and oncogene pathways were significantly upregulated. We suggest that the differentially expressed genes LMNB1 and JUN are potential targets for predicting colorectal cancer metastasis. These results provide clinical guidance in chemotherapy, and offer direction for further research in the mechanism of colorectal cancer metastasis.
The following adverse events have been reported during post-approval use of CHANTIX. Because these events are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency or establish a causal relationship to drug exposure. 

There have been reports of depression, mania, psychosis, hallucinations, paranoia, delusions, homicidal ideation, aggression, hostility, anxiety, and panic, as well as suicidal ideation, suicide attempt, and completed suicide in patients attempting to quit smoking while taking CHANTIX [see Boxed Warning, Warnings and Precautions (5.1)]. Smoking cessation with or without treatment is associated with nicotine withdrawal symptoms and the exacerbation of underlying psychiatric illness. Not all patients had known pre-existing psychiatric illness and not all had discontinued smoking.

There have been reports of hypersensitivity reactions, including angioedema [see Warnings and Precautions (5.2)].

There have also been reports of serious skin reactions, including Stevens-Johnson Syndrome and erythema multiforme, in patients taking CHANTIX [see Warnings and Precautions (5.3)].
Embodiments relate to a medical information processing apparatus, a medical information processing method, and a program. Provided are a medical information processing device, a medical information processing method, and a program, which can facilitate the grasping of a patient state. The medical information processing device of an embodiment includes a reception unit, an extraction unit, and a display control unit. The receiving unit receives a selection of a target part or a target disease. The extraction unit extracts a past 1 st event corresponding to the selected target part or the target disease and a past 2 nd event corresponding to a part or a disease associated with the target part or the target disease. The display control unit displays the 1 st event and the 2 nd event by mapping them on a graph.
Developmental language disorder (DLD) overlaps clinically, genetically, and pathologically with other neurodevelopmental disorders (NDD), corroborating the concept of the NDD continuum. There is a lack of studies to understand the whole genetic spectrum in individuals with DLD. Previously, we recruited 61 probands with severe DLD from 59 families and examined 59 of them and their families using microarray genotyping with a 6.8% diagnostic yield. Herein, we investigated 53 of those probands using whole exome sequencing (WES). Additionally, we used polygenic risk scores (PRS) to understand the within family enrichment of neurodevelopmental difficulties and examine the associations between the results of language-related tests in the probands and language-related PRS. We identified clinically significant variants in four probands, resulting in a 7.5% (4/53) molecular diagnostic yield. Those variants were in PAK2, MED13, PLCB4, and TNRC6B. We also prioritized additional variants for future studies for their role in DLD, including high-impact variants in PARD3 and DIP2C. PRS did not explain the aggregation of neurodevelopmental difficulties in these families. We did not detect significant associations between the language-related tests and language-related PRS. Our results support using WES as the first-tier genetic test for DLD as it can identify monogenic DLD forms. Large-scale sequencing studies for DLD are needed to identify new genes and investigate the polygenic contribution to the condition.
The subjects in the control arm will only complete the baseline and week 13 visits. They will not be asked to make any changes to their diet, only to document their regular diet 3 days a week.
PURPOSE:To obtain the title preparation containing a drug, substance slightly soluble in water as ingredients for matrix solid, polycation and polyanion and capable of releasing a drug at a controlled rate without being affected by physiological factor of alimentary canel when orally administered. CONSTITUTION:The aimed preparation containing (A) a drug, e.g. arotinol hydrochloride, (B) a substance slightly soluble in water, e.g. polyvinyl acetate, ethyl cellulose, hardened oil or carnauba wax, (C) a polycation, e.g. polyvinylacetaldiethylaminoacetate or aminoalkyl methacrylate copolymer and (D) a polyanion, e.g. hydroxypropylmethylcellulose phthalate or methacrylate copolymer at a ratio of these components A, B, C and D of <=50wt.%, 10-70wt.% and 4-10wt.% and 4-10wt.% as ingredients for matrix solid The releasing rate of the drug is not affected by amount or liquid properties of digestive fluid or amount or quality of meal.
A motion adjustment prediction system is described. A scan of a dentition is performed to generate a digital dental model from which a position and orientation of each tooth in the upper and lower dental arches of the dentition is determined with respect to each other tooth. A dentition motion assessment is performed to capture motion data representing a movement of the dental arches relative to each other. A dental treatment plan with dentition adjustment is determined based on the scan and the dentition motion assessment. The dentition adjustment can include a restoration preparation, such as a crown or a bridge, or can include an orthodontic alignment. A motion adjustment is predicted based on the dentition adjustment, and the dental treatment plan is modified based on the predicted motion adjustment.
Patients receive rituximab IV over 2-6 hours once weekly in weeks 1-4 and ipilimumab IV over 90 minutes once weekly in weeks 3, 6, 9, and 12. Patients then receive ipilimumab IV over 90 minutes and rituximab IV over 2-6 hours once every 12 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity.